[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-lateral-sclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-lateral-sclerosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,72,102,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100323309","clinical-procedures-to-support-research-in-als-100323309",false,"NCT03489278","Clinical Procedures to Support Research in ALS","Clinical Procedures to Support Research in ALS (CAPTURE-ALS)","CAPTURE-ALS","Inclusion Criteria:\n\n* Diagnosis of ALS or a related disorder (e.g. primary lateral sclerosis, progressive muscular atrophy).\n* Receiving care at a clinical center that uses Epic as its EHR.\n* Able and willing to provide informed consent (or informed consent obtainable from a designated proxy).\n\nExclusion Criteria:\n\n* Inability to understand English and\u002For Spanish","ALL","18 Years",{"count":20,"type":21},1200,"ESTIMATED","OBSERVATIONAL","The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.",[25,26,27,28],"Amyotrophic Lateral Sclerosis","ALS-Frontotemporal Dementia","Primary Lateral Sclerosis","Progressive Muscular Atrophy","RECRUITING","2026-06-11",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":35,"type":33},"2018-02-15",{"date":37,"type":21},"2034-06",{"name":39,"class":40},"University of Miami","OTHER",11,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100454936","comprehensive-analysis-platform-to-understand-remedy-and-eliminate-als-100454936","NCT05204017","Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS","CAPTURE ALS","\\[PATIENTS\\]\n\nInclusion Criteria:\n\n1. Has ALS, classified as definite, probable, laboratory-supported probable, or possible ALS according to the revised El Escorial criteria or a related neurodegenerative disorder including ALS-FTD, PLS, PMA or asymptomatic individuals with a known ALS mutation (as previously confirmed during regular clinical care)\n2. Be of the age of majority in their province of residence\u002Ftreatment\n3. Have the cognitive capacity to provide informed consent\n4. Have proficiency in English or French in order to understand study instructions and respond to questionnaires\n\nExclusion Criteria:\n\nN\u002FA\n\n\\[HEALTHY CONTROLS\\]\n\nInclusion Criteria:\n\n1. Be between the ages of 40-80 unless age matched to a patient (+\u002F-3 years) who is already enrolled\n2. Be the age of majority in their province of residence\u002Ftreatment\n3. Have the cognitive capacity to provide informed consent\n4. Have proficiency in English of French to understand study instructions and respond to questionnaires\n\nExclusion Criteria:\n\n1. A history of a neurological disease, including Central Nervous System disease (e.g., stroke, head injury, epilepsy) or Peripheral Nervous System disease (neuropathy, myopathy)\n2. A history of psychiatric disease (e.g. depression, bipolar disease) that is clinically diagnosed and\u002For with the current use of psychiatric medications (e.g. antidepressants) for an indication of a psychiatric disease.\n3. Subjects ineligible for an MRI due to a pacemaker or other contraindication according to local MRI policies of the study centre.\n4. Significant claustrophobia that would prohibit an MRI (subjects will be required to lie in an MRI scanner for approximately one hour).",true,{"count":51,"type":21},150,"CAPTURE ALS is a long-term data and biorepository platform that will facilitate future ALS research. CAPTURE ALS will provide the standardized systems and tools necessary to collect, store, and analyze vast amounts of multimodal information about ALS. These multimodal datasets and biosamples will be made available for use by researchers or industry across Canada and around the world in accordance with the CAPTURE ALS Data Sharing Policy to advance research on ALS.",[25,27,28,54],"Frontotemporal Degeneration",[56,57,58,59,60,61],"Biomarker","Biorepository","ALS","Disease Progression","MRI","Biofluids","2026-04-07",{"date":64,"type":33},"2026-04-13",{"date":66,"type":33},"2021-09-12",{"date":68,"type":21},"2031-12",{"name":70,"class":40},"University of Alberta",4,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":41},"100558657","spastic-paraplegia---centers-of-excellence-research-network-100558657","NCT06553976","Spastic Paraplegia - Centers of Excellence Research Network","Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) - Natural History Study Pilot","SP-CERN","Inclusion Criteria:\n\n* Male or female patients of all ages with a clinical and molecular diagnosis of hereditary spastic paraplegia type 4 (SPG4, SPAST) or hereditary spastic paraplegia type 5A (SPG5A, CYP7B1).\n\nExclusion Criteria:\n\n* Not having such a diagnosis and\u002For not being related to such individual.",{"count":81,"type":21},100,"2 Years","The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeutic targets, and d) perform sufficiently powered clinical trials. The current pilot study is aimed at enrolling 100 individuals with hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A).",[85,27,86,87,88,89,90,91,92],"Hereditary Spastic Paraplegia","SPG4","SPG5A","Spastic Paraplegia 4","Spastic Paraplegia 5A","Early Onset Hereditary Spastic Paraplegia","Neuromuscular Diseases","Spastic Paraplegia, Hereditary","2026-03-16",{"date":95,"type":33},"2026-03-18",{"date":97,"type":33},"2024-06-04",{"date":99,"type":21},"2027-06-04",{"name":101,"class":40},"Boston Children's Hospital",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":130,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100629707","effects-of-whole-body-electrical-muscle-stimulation-exercise-on-adults-with-neuromuscular-disease-100629707","NCT07478172","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults withNeuromuscular Disease","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with one or more of the following neuromuscular conditions: Amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscle atrophy, spinal muscular atrophy, postpolio syndrome, inclusion body myositis, pompedisease, fascioscapulohumeral muscular dystrophy, charcot marie tooth disease, chronic inflammatory demyelinating polyneuropathy, hereditary spastic paraplegia, myasthenia gravis, lambert-eaton myasthenic syndrome, postural orthostatic tachycardia syndrome, mitochondrial myopathy, nemaline myopathy, centronuclear myopathy, lumbar radiculopathy, non-specific low back pain.\n* Ability to stand for approximately 15 minutes continuously with or without an assistive device (i.e. the length of time to stand to take a shower, complete meal preparation, wait in line at the bank, etc.)\n* At least some anti-gravity strength in major muscle groups as assessed by manual muscle testing (i.e. 2+\u002F5 strength or better)\n* Medical clearance to participate in an exercise program\n* Ability to provide informed consent\n* Ability to conform to the requirements of the study (i.e. attendance at assessment and intervention visits, maintain current level of non-study physical activity for the duration of the study, no intention to relocate mid-study)\n\nExclusion Criteria:\n\n* Diagnosed with one of the following neuromuscular conditions: Becker's muscular dystrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, myotonic dystrophy type 1 or 2, Freidrich's ataxia, any other NMD with known or suspected cardiac involvement or muscle fiber structural integrity defects.\n* Concurrent participation in another interventional research study\n* Unable to tolerate 15 minutes of continuous standing with or without an assistive device\n* Presence of a pacemaker, metal implants, or other implanted medical devices that could impact participant safety during WB-EMS intervention\n* Presence of cochlear implant, cortical stimulator, deep brain stimulator, ventriculoperitoneal shunt, recent skull defect, seizure in the past 12 months while taking anti-epilepsy medication, or previous serious adverse event with TMS, which could impact participant safety during TMS testing\n* Presence of unstable acute or chronic disease (i.e. renal failure, rheumatologic disease, cardia arrhythmia, neoplasm, uncontrolled hypertension)\n* Known pregnancy at time of screening; verbal screening will occur throughout the study.\n* Presence of a terminal disease (i.e. receiving hospice services)\n* Current or previous use of any drugs known to influence muscle mass or performance within 6 months; these may include but are not limited to anabolic steroids, IGF01, growth hormone, replacement androgen therapy, anti-androgen therapy\n* Presence of an additional neurologic conditions affecting somatosensory or motor function\u002Fcontrol (i.e. Parkinson's disease, Multiple Sclerosis, h\u002Fo stroke, TBI, SCI, ataxia, apraxia, hemiplegia, etc.)\n* Musculoskeletal condition or surgery in the past year that would confound results of exercise interventions (i.e. TKA, THA, RTC repair, spinal fusion)\n* Other medical conditions, signs, or symptoms that would interfere with study conductor interpretation of results as determined by an investigator",{"count":110,"type":21},50,"INTERVENTIONAL",[113],"NA","This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation limits by directly stimulating muscle contractions. Up to 50 adults with conditions like ALS, SMA, and MG will undergo 20-minute supervised WB-EMS sessions (1-2 times weekly for 4-8 weeks) using the Katalyst system. Outcomes include neural excitability (TMS), motor unit behavior (EMG, NCS), functional tests (walk, balance, strength), and patient-reported fatigue, pain, and quality of life. Strict safety monitoring and exclusion criteria are in place. This study will provide preliminary data on WB-EMS as a potential exercise modality for NMD.",[116,25,117,118,27,119,120,121,122,123,124,125,126,127,128,85,129,28],"Neuromuscular Diseases (NMD)","Myasthenia Gravis","Lambert-eaton Myasthenic Syndrome","Spinal Muscular Atrophy","Charcot Marie Tooth Disease (CMT)","Fascioscapulohumeral Muscular Dystrophy","Inclusion Body Myositis","Mitochondrial Myopathy","Nemaline Myopathy","Centronuclear Myopathy","Postpolio Syndrome","Pompe Disease (Late-onset)","Chronic Inflammatory Demyelinating Polyneuropathy","Postural Orthostatic Tachycardia Syndrome (POTS)",[131,132,133,134],"Neuromuscular Disease","Electrical Stimulation","Whole Body stimulation","Exercise intervention","2026-03-12",{"date":137,"type":33},"2026-03-17",{"date":139,"type":33},"2026-03-10",{"date":141,"type":21},"2031-01-07",{"name":143,"class":40},"University of Missouri-Columbia",1,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":49,"sex":17,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":144},"100252610","imaging-biomarkers-in-als-100252610","NCT02567136","Imaging Biomarkers in ALS","A Longitudinal Study of Imaging Biomarkers in Amyotrophic Lateral Sclerosis (ALS)","Inclusion Criteria:\n\n* 21 to 75 years of age inclusive.\n* Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).\n\nALS patients:\n\n* A clinical diagnosis of possible, laboratory-supported probable, probable, or definite ALS, according to a modified El Escorial criteria.\n\nExclusion Criteria:\n\n* Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease, etc).\n* Clinically significant history of unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days.\n* Inability to undergo MRI scanning, including but not limited to unable to remain still in an MRI scanner for more than 30 minutes, claustrophobia, presence of paramagnetic substances or pacemakers in body, weight over 300 lbs, or in the opinion of the investigator, if there is a strong likelihood that the subject would not be able to lie flat comfortably for 75-90 minutes.\n* The subject requires assistance to ambulate OR climb stairs, unless in the opinion of the investigator, and based upon the subject's rate of disease progression, the subject is likely to be able to participate in the MRI screening 12 months after enrollment.","21 Years","75 Years",{"count":155,"type":21},30,"The purpose of the study is to determine if we are able to find one or more biomarkers of Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS) using magnetic resonance imaging (MRI) scans at different levels, 3 tesla (3T) and 7 tesla (7T). A biomarker is a measurable characteristic that can be used as an indicator of a particular disease state. Identifying biomarkers of a disease can lead to a better understanding of the disease as well as improved treatments. This study will enroll patients with ALS, PLS, and healthy controls.",[25,27],"2025-11-24",{"date":160,"type":33},"2025-12-02",{"date":162,"type":4},"2015-09",{"date":164,"type":21},"2031-09-30",{"name":166,"class":40},"University of Minnesota"]